Omnicell Inc.

Omnicell is a provider of automation and business analytics software solutions for patient-centric medication and supply management. The company's main products are automated medication, supply control systems and medication adherence solutions which are sold in healthcare industry. The company is organized in two operating segments: Automation and Analytics, which designs, manufactures, sells and services medication and supplies dispensing systems, pharmacy inventory management systems, and related software; and Medication Adherence, which develops, manufactures and sells consumable medication blister cards, packaging equipment, medication synchronization platform, and ancillary products and services.
  • TickerOMCL
  • ISINUS68213N1090
  • ExchangeNASDAQ Stock Market
  • SectorHealth Care Equipment & Services
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

1 director sold

A director at Omnicell Inc sold 5,000 shares at 70.296USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

Valens Research

UAFRS vs As Reported Weekly Highlights - 2018 08 01

This week, Valens identified distortions and the corresponding adjustments to correct for those distortions for ORCL, IAC, and OMCL.

1 director sold

A director at Omnicell Inc sold 5,000 shares at 70.296USD and the significance rating of the trade was 50/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of board me...

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

ValuEngine Rating and Forecast Report for OMCL

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • The U.S. dollar is breaking its 16-month uptrend and is declining through its 200-day moving average and Gold is breaking to 6-year price highs. RS appears to be staging a reversal at a support level. (ex. GC00, GDX) • A number of Healthcare Sector names are breaking out or staging reversals. (ex. ITGR, CHE, XRAY, OMCL, MOH, WCG, ARWR, INCY, GILD, VRTX, IQV, MEDP, and CTLT)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Gold is staging a massive breakout above the $1360 level. Major H&S bottoms can be seen across the group (ex, NEM, RGLD) • Energy related names are attempting to carve out reversals. We prefer the names that held up well during the Crude oil decline. (ex. HLX, PUMP, FTI, CKH, PSX) • A number of Biotech names are breaking out of bases and reflect RS leadership. (ex. OMCL, RGEN, INCY, and ANIP)

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Health Care remains a bright spot and many individual names are breaking to RS highs. • Many Consumer Cyclical names such as NKE and CMG are emerging as leadership. • Many Semi and Semiconductor supplier names are staging Price and RS reversals.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • The Staples Sector continues to develop positive price and RS reversals. • A number of Insurance related names are breaking to new price and RS highs. • Semis and Semi-Suppliers continue to weaken. We highlighted Semi-Suppliers in March as showing top patterns; many are breaking to 52-week lows. • Many Energy E&P stocks are developing top patterns.

Dave Nicoski ...
  • Ross LaDuke

Vital Signs: Actionable charts

Key Points: • Property & Casualty Insurance names are staging price and RS reversal and/or breakouts. • Airlines are staging price and SR reversals to the upside and/or are breaking out. • Railroad related names are breaking out. • We have been bearish on much of the Semiconductor and Suppliers industry since February; however we are seeing some near term reversals at support levels. We will keep you posted of any further changes.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch